CME Group stock has delivered a 63.7% gain over the past five years, yet the latest valuation checks, including an Excess Returns intrinsic value estimate and market multiples, suggest the shares now trade closer to a full price than a clear bargain.

• CME Group has returned 63.7% over five years, which means long term holders have already captured a solid chunk of value from the stock.
• New product launches in areas like AI compute and sports related futures can support expectations for future cash flows. At the same time, any setback in product uptake or trading volumes may limit how much investors are willing to pay for those prospects.
• The company scores 2 out of 6 on broader valuation checks, which suggests CME Group is not obviously cheap on most standard measures.

The issue now is whether CME Group's current price already reflects these growth opportunities, or if there is still room relative to its intrinsic value estimate.

Does CME Group Look Fairly Valued on Excess Returns?

The Excess Returns model looks at how much value CME Group creates above the return investors typically require on its equity. For CME Group, the framework points to a business earning more than its assumed cost of equity on a fairly stable capital base.

The model uses a Book Value of $73.82 per share and a Stable EPS estimate of $13.42 per share, based on weighted future Return on Equity inputs from four analysts. Against a Cost of Equity of $6.63 per share, this implies an Excess Return of $6.79 per share supported by an average Return on Equity of 15.94%. On these inputs and a Stable Book Value of $84.19 per share, the Excess Returns valuation arrives at an intrinsic value of $246.94 per share, which sits below the current share price and implies the stock screens around 6.2% overvalued. The planned launch of AI compute futures in partnership with Silicon Data helps explain why investors are willing to pay a premium to these intrinsic value estimates.

On this model, CME Group stock currently looks about fairly valued, with the market price sitting modestly above the Excess Returns estimate.

CME Group is fairly valued according to our Excess Returns, but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

Does CME Group Look Pricey on Earnings?

The P/E ratio is a decent shorthand here because CME Group is profitable and investors often focus on its earnings power. CME Group currently trades on a P/E of about 22.1x, which sits below the broader Capital Markets industry average of 37.5x but above the peer group average of 25.6x.

On the more tailored fair P/E estimate of 16.0x, which factors in CME Group's margins, scale, sector and risk profile, the stock appears relatively expensive. The current multiple is several turns higher than that fair ratio, so the shares look priced for a comparatively strong earnings profile relative to what this model would normally assign.

On the P/E multiple, CME Group stock currently screens as overvalued relative to its fair ratio benchmark.

The CME Group Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the earlier valuation checks leave off and focus on what would need to be true for CME Group's current share price to move meaningfully higher or lower over time. Each narrative sets out the assumptions behind its fair value for CME Group, including expectations for growth, margins and earnings, so you can compare those inputs with the company’s reported results as they come through. These are available on Simply Wall St's Community page.

Be one of the first voices in the Simply Wall St community to set out a number driven case on CME Group, including a view on whether the planned AI compute and NHL futures launches and expanded 24/7 metals trading ultimately support today's pricing. Share your Narrative, lock in your assumptions on growth, margins and execution, and see how your thesis holds up as new results and product updates come through.

Do you think there's more to the story for CME Group? Head over to our Community to see what others are saying!

The Bottom Line

CME Group now sits in a zone where the intrinsic value estimate flags only a modest premium, while the tailored P/E view points to the stock as overvalued relative to its fair ratio benchmark. The broader valuation score also looks weak, which supports the idea that the easy valuation case has passed and expectations are doing more of the heavy lifting. From here, the key question is whether new contracts such as AI compute and sports related futures, along with core trading activity, can support the current multiple rather than see it move closer to the fair ratio over time.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.